NCT02602704 is a Phase 4 clinical trial of Bazedoxifene in Arthritis, Rheumatoid, sponsored by Hanyang University.

Who is sponsoring NCT02602704?

NCT02602704 is sponsored by Hanyang University.

What drugs are being tested in NCT02602704?

Interventions in NCT02602704: Bazedoxifene, Calcium/Vit D.

What condition does NCT02602704 study?

NCT02602704 studies Arthritis, Rheumatoid.

Is NCT02602704 still recruiting?

NCT02602704 is currently completed. Last updated 12 August 2020.

Last reviewed 2020-08-12 · How we verify

NCT02602704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Completed Phase 4 Last updated 12 August 2020

What this trial tests

Phase 4 trial testing Bazedoxifene in Arthritis, Rheumatoid in 114 participants. Completed in 1 December 2018.

Timeline

29 December 2015

Primary endpoint
11 October 2017

1 December 2018

Quick facts

Lead sponsor	Hanyang University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	114
Start date	29 December 2015
Primary completion	11 October 2017
Estimated completion	1 December 2018
Sites	1 location across South Korea

Drugs / interventions tested

Bazedoxifene (BAZEDOXIFENE) — full drug profile →
Calcium/Vit D — full drug profile →

Conditions studied

Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →

Sponsor

Hanyang University

Who can join

45 and older, female only, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* The purpose of this study is to study the effectiveness of bazedoxifene in preventing loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs. * This is a randomized, controlled, open-label extension study for 48 or 56 weeks. At study entry, all patients will receive elemental calcium (1200 mg daily) and vitamin D (800 IU daily) and will be randomized by blocks of two to receive either bazedoxifene (20 mg/day) or none.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
Cho SK, Kim H, Lee J, Nam E, et al · · 2021 · cited 8× · PMID 34215316 · DOI 10.1186/s13075-021-02564-1
Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study.
Cho SK, Song YJ, Kim HW, Nam E, et al · · 2025 · cited 1× · PMID 38366621 · DOI 10.1093/rheumatology/keae109

Verify or expand the search:

Other trials of Bazedoxifene

Trials testing the same drug.

NCT02448771 — A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer · Phase 1, PHASE2 · completed
NCT01416194 — Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU) · completed

Other recruiting trials for Arthritis, Rheumatoid

Currently open trials in the same condition.

NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting

Other Hanyang University trials

Trials by the same sponsor.

NCT06230302 — Efficacy and Safety of Kefir Whey Postbiotics · NA · unknown
NCT05579158 — Effects of Time-restricted Eating Supported by Mobile Technology in Patients With Non-alcoholic Fatty Liver Disease: Ran · NA · completed
NCT06812091 — Human Microbiome Research and Development for Overcoming Pediatric Diseases · recruiting
NCT04449224 — Comparative Effectiveness of Targeted Therapy in RA Patients · unknown
NCT03983408 — Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02602704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanyang University
Last refreshed: 12 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02602704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing